Clinical Trial Update: Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the cumulative skin irritation potential of a 15 mg nicotine transdermal patch for smoking cessation; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Nicotine patch (nicotine patch)

Snippet

Sponsor: McNeil AB | Conditions: Smoking Cessation | Phase 1 | Status: COMPLETED